Cytokines in the Treatment of Cancer

par Conlon, Kevin C., Miljkovic, Milos D., Waldmann, Thomas A.
Publié dans J Interferon Cytokine Res (2019)

Interleukin-15 (dys)regulation of lymphoid homeostasis: Implications for therapy of autoimmunity and cancer

par Waldmann, Thomas A., Miljkovic, Milos D., Conlon, Kevin C.
Publié dans J Exp Med (2019)

IL-15 in the Combination Immunotherapy of Cancer

par Waldmann, Thomas A., Dubois, Sigrid, Miljkovic, Milos D., Conlon, Kevin C.
Publié dans Front Immunol (2020)

Intraductal Papillary Mucinous Neoplasms of the Pancreas: An Analysis of Clinicopathologic Features and Outcome

par D'Angelica, Michael, Brennan, Murray F., Suriawinata, Arief A., Klimstra, David, Conlon, Kevin C.
Publié 2004

Association of Preoperative Biliary Drainage With Postoperative Outcome Following Pancreaticoduodenectomy

par Povoski, Stephen P., Karpeh, Martin S., Conlon, Kevin C., Blumgart, Leslie H., Brennan, Murray F.
Publié 1999

Multi-Omic Biomarkers as Potential Tools for the Characterisation of Pancreatic Cystic Lesions and Cancer: Innovative Patient Data Integration

par Kane, Laura E., Mellotte, Gregory S., Conlon, Kevin C., Ryan, Barbara M., Maher, Stephen G.
Publié dans Cancers (Basel) (2021)

Chronic pancreatitis: A diagnostic dilemma

par Duggan, Sinead N, Ní Chonchubhair, Hazel M, Lawal, Oladapo, O’Connor, Donal B, Conlon, Kevin C
Publié dans World J Gastroenterol (2016)

Prospective Randomized Clinical Trial of the Value of Intraperitoneal Drainage After Pancreatic Resection

par Conlon, Kevin C., Labow, Daniel, Leung, Dennis, Smith, Alex, Jarnagin, William, Coit, Daniel G., Merchant, Nipum, Brennan, Murray F.
Publié 2001

IL15 Infusion of Cancer Patients Expands the Subpopulation of Cytotoxic CD56(bright) NK Cells and Increases NK-Cell Cytokine Release Capabilities

par Dubois, Sigrid, Conlon, Kevin C., Müller, Jürgen R., Hsu-Albert, Jennifer, Beltran, Nancy, Bryant, Bonita R., Waldmann, Thomas A.
Publié dans Cancer Immunol Res (2017)

Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity

par Kreitman, Robert J., Stetler-Stevenson, Maryalice, Jaffe, Elaine S., Conlon, Kevin C., Steinberg, Seth M., Wilson, Wyndham, Waldmann, Thomas A., Pastan, Ira
Publié dans Clin Cancer Res (2015)

Incidence and risk factors of delirium in patients post pancreaticoduodenectomy

par Gallagher, Tom K, McErlean, Sarah, O'Farrell, Aimee, Hoti, Emir, Maguire, Donal, Traynor, Oscar J, Conlon, Kevin C, Geoghegan, Justin G
Publié 2014

Augmented efficacy with the combination of blockade of the NOTCH-1 pathway, Bortezomib and Romidepsin in a murine MT-1 adult T cell leukemia model

par Yu, Ping, Petrus, Michael N., Ju, Wei, Zhang, Meili, Conlon, Kevin C., Nakagawa, Masao, Maeda, Michiyuki, Bamford, Richard N., Waldmann, Thomas A.
Publié dans Leukemia (2014)

Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia

par Chen, Jing, Pise-Masison, Cynthia A., Shih, Joanna H., Morris, John C., Janik, John E., Conlon, Kevin C., Keating, Anne, Waldmann, Thomas A.
Publié 2013

Medication details documented on hospital discharge: cross-sectional observational study of factors associated with medication non-reconciliation

par Grimes, Tamasine C, Duggan, Catherine A, Delaney, Tim P, Graham, Ian M, Conlon, Kevin C, Deasy, Evelyn, Jago-Byrne, Marie-Claire, O' Brien, Paul
Publié 2011

Enhanced efficacy of JAK1 inhibitor with mTORC1/C2 targeting in smoldering/chronic adult T cell leukemia

par Daenthanasanmak, Anusara, Lin, Yuquan, Zhang, Meili, Bryant, Bonita R., Petrus, Michael N., Bamford, Richard N., Thomas, Craig J., Miljkovic, Milos D., Conlon, Kevin C., Waldmann, Thomas A.
Publié dans Transl Oncol (2020)

IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective γ-chain cytokines, decreases leukemic T-cell viability

par Wang, T. Tiffany, Yang, Jun, Zhang, Yong, Zhang, Meili, Dubois, Sigrid, Conlon, Kevin C., Tagaya, Yutaka, Hamele, Cait E., Dighe, Shubha, Olson, Thomas L., Feith, David J., Azimi, Nazli, Waldmann, Thomas A., Loughran, Thomas P.
Publié dans Leukemia (2018)

Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies

par Dubois, Sigrid P, Miljkovic, Milos D, Fleisher, Thomas A, Pittaluga, Stefania, Hsu-Albert, Jennifer, Bryant, Bonita R, Petrus, Michael N, Perera, Liyanage P, Müller, Jürgen R, Shih, Joanna H, Waldmann, Thomas A, Conlon, Kevin C
Publié dans J Immunother Cancer (2021)

First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia

par Cooley, Sarah, He, Fiona, Bachanova, Veronika, Vercellotti, Gregory M., DeFor, Todd E., Curtsinger, Julie M., Robertson, Paul, Grzywacz, Bartosz, Conlon, Kevin C., Waldmann, Thomas A., McKenna, David H., Blazar, Bruce R., Weisdorf, Daniel J., Miller, Jeffrey S.
Publié dans Blood Adv (2019)

Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia

par Zhang, Meili, Griner, Lesley A Mathews, Ju, Wei, Duveau, Damien Y, Guha, Rajarshi, Petrus, Michael, Wen, Bernard, Maeda, Michiyuki, Shinn, Paul, Ferrer, Marc, Conlon, Kevin C, Bamford, Richard, O'Shea, John J, Thomas, Craig J, Waldmann, Thomas A
Publié dans Retrovirology (2015)

CITN11-02 interim trial results: subcutaneous administration of recombinant human IL-15 (rhIL-15) is associated with expansion of peripheral blood CD56+ NK cells and CD8+ T cells

par Morishima, Chihiro, McNeel, Douglas G, Patel, Manish R, Kohrt, Holbrook E, Waldmann, Thomas A, Thompson, John A, Conlon, Kevin C, Sondel, Paul M, Wakelee, Heather A, Apodaca, Minjun C, Fling, Steven P, Disis, Mary L, Creekmore, Stephen P, Miller, Jeffrey S
Publié dans J Immunother Cancer (2015)